SCHEDULE: Vanguard Group Amends Eli Lilly Stake to 8.55%

The Vanguard Group has filed an amendment to its Schedule 13G, disclosing an 8.55% beneficial ownership in Eli Lilly & Co as of September 30, 2025.

Summary

• The Vanguard Group reported beneficial ownership of 80,952,595 shares of Eli Lilly & Co common stock.
• This represents 8.55% of the class of securities.
• Vanguard holds sole dispositive power over 73,223,987 shares and shared dispositive power over 7,728,608 shares.
• Vanguard holds shared voting power over 4,843,238 shares and no sole voting power.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Eli Lilly & Co.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of passive institutional ownership and does not contain information that would inherently be positive or negative for the company's operational or financial performance. It is a neutral, factual update.

Future Outlook

NA

Industry Context

This filing reflects a routine disclosure by a major institutional investor, The Vanguard Group, regarding its passive ownership stake in a prominent pharmaceutical company, Eli Lilly & Co. Such large, passive holdings are common for index fund managers and typically do not indicate a change in strategic direction for either the investor or the company, but rather reflect the company's inclusion in various investment portfolios.

Comparison to Industry Standards

• The Vanguard Group, as one of the world's largest investment management companies, routinely holds significant passive stakes (often exceeding 5%) in numerous publicly traded companies, including those in the pharmaceutical sector like Eli Lilly & Co. This level of ownership is consistent with its role as a major index fund provider.
• Compared to activist investors, Vanguard's stated purpose of holding shares 'in the ordinary course of business' and 'not for the purpose of or with the effect of changing or influencing the control' aligns with its established passive investment strategy, contrasting with firms like Elliott Management or Starboard Value that actively seek to influence corporate strategy.

Stakeholder Impact

• Shareholders: The filing confirms a significant, stable institutional ownership base, which can contribute to market liquidity and stability.
• The Vanguard Group's clients: These clients are the beneficial owners of the shares, receiving dividends and proceeds from sales, consistent with their investment objectives.

Key Dates

Keywords

Eli Lilly & Co, Vanguard Group, Schedule 13G, Institutional Ownership, Common Stock, Pharmaceuticals, Investment Adviser